For example, CHIP can target tau, a key player in Alzheimer’s disease, but dysregulated CHIP fails to degrade tau, leading to tau aggregates and Alzheimer’s disease development (12). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.